LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

12.92 1.65

Resumen

Variación precio

24h

Actual

Mínimo

12.54

Máximo

13.03

Métricas clave

By Trading Economics

Ingresos

-22M

-274M

Ventas

-5.4M

2.2M

BPA

-0.29

Margen de beneficios

-12,622.627

Empleados

750

EBITDA

-284K

-284M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+26.08% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

528M

8.2B

Apertura anterior

11.27

Cierre anterior

12.92

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2025, 23:59 UTC

Adquisiciones, fusiones, absorciones

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept 2025, 22:02 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Tron Shares Rise After New Investment From Bravemorning

8 sept 2025, 16:14 UTC

Principales Movimientos del Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept 2025, 22:56 UTC

Charlas de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept 2025, 22:23 UTC

Charlas de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept 2025, 21:51 UTC

Charlas de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept 2025, 21:47 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 sept 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 19:33 UTC

Charlas de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept 2025, 19:22 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept 2025, 19:02 UTC

Charlas de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept 2025, 17:29 UTC

Charlas de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept 2025, 16:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept 2025, 16:36 UTC

Charlas de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 16:16 UTC

Ganancias

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 sept 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

26.08% repunte

Estimación a 12 Meses

Media 16.29 USD  26.08%

Máximo 19 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

173 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat